Their relationship is still going strong. Patrick Mahomes and Travis Kelce said that it was 'a great honor' for the president ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...

New research explores the wide world of the positives, and potential drawbacks, of new obesity medications. And each brings a new consideration for physicians.

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly is expanding the ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

The GLP-1 compound drug sold by Hims and Hers is not approved by the FDA and its Super Bowl ad fails to list any risks ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...